NCT02859727View on ClinicalTrials.gov

Extension to the Study of Efficacy of CDZ173 in Patients with APDS/PASLI

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 8, 2016

Primary Completion Date

January 30, 2025

Study Completion Date

January 30, 2025

Conditions
Activated PI3Kdelta Syndrome (APDS); PASLI Disease
Interventions
DRUG

CDZ173

140 mg/day

Trial Locations (8)

15006

Pharming Investigative Site, Prague

20892

Pharming Investigative Site, Bethesda

25123

Pharming Investigative Site, Brescia

90127

Pharming Investigative Site, Palermo

117198

Pharming Investigative Site, Moscow

223053

Pharming Investigative Site, Minsk

01307

Pharming Investigative Site, Dresden

3000 CA

Pharming Investigative Site, Rotterdam

Sponsors
All Listed Sponsors
lead

Pharming Technologies B.V.

INDUSTRY

NCT02859727 - Extension to the Study of Efficacy of CDZ173 in Patients with APDS/PASLI | Biotech Hunter | Biotech Hunter